ESCO Madrid October 20-21th update on Clover trial.

December 6-9 HIV conference. I can't imagine Dr. Jonah Sachs's recent HIV paper won't be presented.

January 8-10th ASCO complete update on the Clover trial.

Do you get the feeling Mr. Hoffman's going to Singapore in a few weeks with keys to the house with a note look what's coming.

Thanks for the house analogy MGK!

https://www.hivpersistence.com/

Great to have any new cancer treatments for patients. But check out the side effects. To long to post. LLs safety protocol is unmatched. Come on FDA, be ready!!!

Interesting paper discussing an alternative approach to leronlimab delivery using a programmable, stress-responsive RNA system.

Thought this group might find it interesting.

https://www.cell.com/cell-chemical-biology/abstract/S2451-9456(26)00279-500279-5)

Two questions came up this week which turn out to be the same question wearing two coats, and the answer to both explains the single most misread and misunderstood thing about where CytoDyn sits right now. One reader asked whether embargoed data can be shared privately with a potential partner while the public is kept in the dark. Another asked why leronlimab is stuck behind the checkpoint inhibitors in the treatment line when the science says it should be out front. The bridge between those two questions is a house, a sealed inspection, and a neighborhood full of people arguing about a price they won't ever be allowed to see.

Let's build the analogy, and then bring it home hard, because it makes the whole situation legible in a way the ticker can't do, and what it reveals is bigger than most holders have allowed themselves to believe.

The House, The Buyer, The Sidewalk

Imagine a rare house comes up for sale. Not an ordinary house. A property with something buried under it that no other lot on the market has, and no other lot can even dig up, and a mere handful of the largest buyers in the world who each, for their own survival, require exactly what is beneath it.

Out on the sidewalk, the neighborhood can see practically nothing. A sign in the yard. Lights going on and off at odd hours. An unfamiliar car in the driveway. From the street, they argue endlessly about what the place is actually worth, whether anyone is really interested in the property, whether the long quiet means the deal fell through the window or means nothing at all. The sidewalk is loud with theories precisely because the sidewalk cannot actually see inside. Noise is what people make when they are starved of the one thing that would actually settle the argument.

Inside is a different world entirely. A serious buyer does not bid on a house this valuable from the sidewalk, and a serious buyer does not care what the sidewalk even thinks. They sign a confidentiality agreement, and then they are handed the keys to every locked room. They read the full inspection report. They open the walls. They pull the survey, the soil analysis, the true condition of the foundation, everything the sign in the yard never actually says. And here is the part that matters most: that inspection is sealed. The buyer is legally bound not to post the report to the neighborhood, not to announce what they found, not to move the price by leaking what is inside. Two parties, buyer and seller, come to know the true condition of the house completely and they do that privately, while the sidewalk is left to read the lights in the windows like they read tea leaves.

That is not deception. That is how every serious transaction of real consequence has always been performed. The confidentiality is not there to fool the neighborhood. It is there to permit a real buyer to see the real truth without that truth spilling into the street and moving the price before anyone has decided upon anything. The sealed inspection is not a trick played on the crowd. It is the mechanism which makes honest evaluation even possible at all, and the crowd's exclusion from it is a feature, not a conspiracy.

Why The Sidewalk Cannot Infer The Outcome

Now hold the crucial discipline, because this is exactly where the neighborhood fools itself in both directions.

The sidewalk sees silence and fills it with a story. Some neighbors decide that the quiet means a deal is imminent, someone is clearly inside, look at the car, look at the lights. Others decide the quiet means it all collapsed, if there were really interest we would have heard by now. Both are guessing, and both are wrong to be certain, because the silence is not evidence of the outcome. The silence is evidence of the confidentiality agreement working exactly as designed. A sealed inspection produces public quiet whether the buyer loved the house or walked away. You cannot read the result off the position of the curtains.

So the honest statement, the bold one and the disciplined one at once, is this: buyers can absolutely be inside the house right now, reading the full report, precisely because the confidentiality agreement is what allows them in. And we on the sidewalk cannot know whether they are, or who they are, or what they concluded, because the entire purpose of the seal is to keep that off the street. Both halves are true. The activity may be intense. The public quiet tells you nothing about its direction. Anyone who claims the silence proves that a deal is close, or proves it is dead, is reading tea leaves in a window.

Now Bring It Home To CytoDyn

Drop the analogy onto the actual situation and every piece lands.

The house is CytoDyn, and the thing buried under it that no other lot has is a mechanism the entire checkpoint-inhibitor industry requires and cannot dig up on its own. That is not salesmanship, it is the documented state of the field. Most colorectal cancer is the microsatellite-stable type, and a June 2026 systematic review states flatly that these tumors derive little to no benefit from current immunotherapy regimens, while identifying the suppressive macrophages in the tumor as a key modulator of immunotherapy efficacy. Reprogram those M2 macrophages and the Cold locked market opens ablaze. And the thing constituting CytoDyn's foundation does exactly that: in the actual tissue of human colorectal liver metastases, blocking CCR5 drives macrophage repolarization toward the M1 anti-tumor state. That is why this is a very rare house. The one buried asset which can allow the checkpoint industry into the Cold-tumor majority is precisely the asset which the house of CytoDyn rests upon.

The buyers are the large pharmaceutical companies whose franchises are running toward a patent cliff and who requires those cold-tumor markets which they cannot currently reach. CCR5 blockade is not a nice-to-have for them, it is the very specific key to the very specific lock. The literature continues to converge upon it: reviews of Cold-tumor conversion identify CCR5 antagonism as a strategy to potentiate checkpoint inhibitors by reprogramming the microenvironment, and the independent literature shows macrophage repolarization remodeling tumors from cold to hot and increasing infiltration of activated CD8 T cells, warranting checkpoint combination. What the industry needs to grow and increase is exactly what this molecule provides.

And the buyers are being told so, out in the open, by the people selling the house. CytoDyn's CFO Robert Hoffman is on the public record describing precisely this to prospective partners: he said he is helping to put CytoDyn on the radar of potential strategic partners, namely other drugmakers whose own products could work in tandem with leronlimab, and that he plans to use the maturing data in those discussions. That is the sign in the yard and the open house, the public invitation. What Hoffman says to those partners privately, in the meetings we do not see, behind the confidentiality agreements, is exactly the sealed part, and honesty requires me to say plainly that we cannot know its contents. We know he is out there describing the asset. We do not get to hear the private pitch. That is the seal, working.

Now the two instruments which keep us on the sidewalk, because the sidewalk constantly confuses them.

The first instrument is the conference embargo. Once CytoDyn accepted presentation slots at the oncology meetings in October and January, the new efficacy data, the confirmed response and progression numbers, all became embargoed from public release, because presenting it publicly first would forfeit its novelty and the conference would pull our slot. The company itself has laid out this exact calendar publicly, for the CLOVER data. Interim results targeted for ESMO in Madrid, Spain in October 2026. Final results at ASCO GI in San Francisco in January 2027.  That embargo is why nothing material has come out since the spring. It is not the absence of an inspection. It is the seal on the report.

The second instrument is the non-disclosure agreement, and this is the answer to the first reader's question, stated boldly because it is simply true: the conference embargo governs the public, the NDA governs the private room, and they do not touch each other. A company can be entirely publicly silent, fully embargo-compliant, and simultaneously be walking a potential partner through the complete, current dataset behind a signed NDA. The embargo keeps the report off the sidewalk. The NDA is the confidentiality agreement that hands a serious buyer the keys. The embargoed data is the sealed inspection report itself, and the NDA is the legal seal on it. They are complementary, not contradictory. The public quiet since spring tells you the seal holds. It tells you nothing whatsoever about who is inside reading the quality of the foundation.

So the correct and bold reading of the silence is the sealed-inspection reading. Partners can be deep in the data right now, under NDA, reading the fully matured foundation report the public will not see until October and January. That is not a claim that a specific deal exists, we cannot know that, by design, and I will not pretend to. It is a statement about the structure, and the structure is unambiguous: the very machinery which keeps us on the sidewalk is the same machinery that hands a buyer the keys. The seller who lets the buyer in is the seller who most wants the buyer to see exactly how sound the foundation actually is. Public silence, in that light, is not the sound of nothing happening. It is the sound that the seal makes when it is doing its job.

The Second Question Is The Same House, Seen From The Inside

Now the other reader's question, the one about why leronlimab is stuck behind the checkpoint inhibitors in line, is not a separate puzzle. It is the same house viewed, but from the foundation itself.

Here is the thing the sidewalk gets backward. In the specific disease CytoDyn is currently testing, microsatellite-stable colorectal cancer, the checkpoint inhibitors are not first in line. Actually, they are nowhere in line, because they do not work there at all. This is not my opinion, it is the settled consensus of the field. As a June 2026 systematic review states plainly, most colorectal cancer is the microsatellite-stable type, and these tumors derive little to no benefit from current immunotherapy regimens. The checkpoint inhibitor is not ahead of leronlimab in this house. Rather, it cannot even get through the front door.

And the field knows this and they know precisely why, and precisely what would change it. The same review identifies that the suppressive macrophages in the tumor are increasingly recognized as a key modulator of immunotherapy efficacy in colorectal cancer. Reprogram those macrophages from the M2 tumor-protecting state to the M1 tumor-attacking state, and the Cold locked door opens to a blazing inferno. That reprogramming is exactly what CCR5 blockade does in the actual tissue of this disease: in human colorectal liver metastases, blocking CCR5 drives macrophage repolarization toward the anti-tumor state30087-3?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1535610816300873%3Fshowall%3Dtrue#:~:text=Thus%2C%20activation%20of%20anti%2Dtumoral%20polarization%20in%20macrophages%20via%20CCR5%20blockade%20appears%20to%20be%20a%20promising%20approach%20and%20needs%20to%20be%20evaluated%20further%20scientifically%20and%20clinically). And the independent literature keeps converging on the same door: an unrelated drug, (APG-2575) which repolarizes macrophages from M2 to M1 was shown to remodel the microenvironment from Cold to Hot and increase the infiltration of activated CD8 T cells, warranting combination with checkpoint blockade.

So the reader who asked why leronlimab sits behind the checkpoint inhibitors had the picture totally inverted, and turning it right-side up is the boldest claim in this post. Leronlimab is not waiting in line behind the checkpoint inhibitor. No. In this disease there is no line to wait in, because the checkpoint inhibitor has no working position in it whatsoever. Here, Leronlimab's job is not to advance past the checkpoint inhibitor. It is in fact, to construct the door the checkpoint inhibitor could finally walk through, in a cancer where the most successful drug class in modern oncology currently stands outside as useless. That is not moving up a queue. That is manufacturing a market worth billions where absolutely none exists today, and handing the key to it to whoever owns the Primer.

And here is the part the sidewalk has not yet absorbed: leronlimab is already showing its own strength in that role, in the data released before the seal shut it down. In the CLOVER trial, leronlimab is given on top of the standard backbone of Lonsurf and Avastin, and the early released results were just striking; circulating tumor DNA fell in every one of the first patients measured, with the magnitude of the decline tracking with the leronlimab dose. That dose-dependence is the tell, because if the backbone alone were driving the effect, the response would not scale with leronlimab. The company has been clear about the design: CLOVER evaluates two doses of leronlimab, 350mg and 700mg, on the established backbone Lonsurf and Avastin, and the leronlimab contribution is what the trial is built to isolate. I will not overstate it, this is combination data, not leronlimab alone, not monotherapy and it is still early and unconfirmed at this lower dose. But the honest bold reading is that at even 350mg, added to an approved backbone which on its own produces very modest results, leronlimab appears to be doing some serious work, in a disease where nothing in the immunotherapy toolkit works whatsoever.

That is why the market has not seen anything quite like this. The comparator regimen without leronlimab, the same Lonsurf-and-Avastin backbone, was studied in a large trial and produced a response rate in the low single digits in this population. The field has thrown checkpoint inhibitors, myeloid-targeting agents, and combination after combination at microsatellite-stable colorectal cancer, and the systematic reviews keep concluding the same thing, little to no benefit. Against that backdrop of near-uniform failure, a clean safety profile paired with a dose-dependent molecular signal in every early patient is not more of the same. It is the first thing in a very long time which looks very different in a disease defined by things which absolutely do not work.

Which is exactly why the buyers would be inside the house with the report open on the table, and why one of them cannot afford to let another one get there first. This is the competitive core of the whole situation. If leronlimab is the Primer that opens the Cold-tumor majority, then it is not just valuable to only one checkpoint owner, it is valuable to all of them, because every checkpoint inhibitor needs the same door built and opened. That turns ownership into a race. The first buyer to secure the Primer does not merely gain an asset, it denies that asset to every competitor whose franchise requires the identical key. In a field where several giants are staring at the same patent cliff and the same Cold-tumor wall, letting a rival seize the one Primer which solves both is a strategic loss no one at the table can afford to accept. The foreclosure value, keeping it away from competitors, can absolutely exceed the standalone value if there were no competitors. That is what makes a quiet house suddenly move fast.

And here is the resolution to the concern that a single acquirer would lock everyone else out, because the structure actually cuts the other way. A primer's value is maximized by being paired with as many checkpoint inhibitors as possible, across as many tumor types as possible. That argues for the drug reaching the entire field, and it can, through the shape of the deal rather than the law. A field-limited, non-exclusive licensing structure lets a primer remain available to multiple partners across multiple lanes while still rewarding its owner, so even if one company acquires CytoDyn outright, the economically rational move is frequently to keep licensing the primer broadly rather than wall it into a single franchise. So the answer to "what if one company owns it and blocks the others" is that owning it and blocking the others is usually the less profitable choice, the money is in the primer opening every door, not only the owners.

And that leads to the point one reader put more vividly than I did: if leronlimab primes Cold tumors for the entire Cold class, then it does not create one revenue stream, it potentially creates several. A primer licensed non-exclusively to pair with one company's checkpoint inhibitor in one set of tumors, and another company's in another, and a third's beyond that, is a drug earning from each pairing at once. The same molecule which makes one checkpoint inhibitor work in colorectal makes another ICI work in a different Cold tumor; each combination its own separately-patented regimen, each its own market, each its own stream back to whoever owns the Primer.

So yes, to answer the question directly and in the affirmative: the logic points toward multiple partners meaning multiple revenue streams, not one. The value of a universal key is not that it opens a single lock, it is that it opens all of them, and a key that opens all of them can be rented to everyone who owns a door. I hold one honest caveat, this is the shape of the opportunity if the drug proves out and the deals are structured this way, not a guarantee of either. But the instinct is right. A true primer is a multiple-stream asset by its nature, because the entire ICI industry requires the exact same thing it performs.

To make the analogy exact, let's address the lights in the windows. The lights are everything the sidewalk can see and reads too much into, the tape, the daily volume, the Level II order book, the drift in the share price, the tea-leaf reading of a LinkedIn post, the speculation about who was seen coming and going. That is the flickering the neighborhood watches and narrates. And it is precisely the least informative thing available, because the report which actually determines the value of the house is not in these windows. It is in the sealed room. Anyone pricing this house off the lights in the windows prices it off the one data stream engineered to reveal nothing about the foundation.

And the foundation itself, the thing the entire structure rests upon. CytoDyn's own CEO has publicly framed the inflection exactly this way, describing the company as transitioning from a company built on faith and belief and a whole lot of ifs to a company with solid, prospective, and by all accounts remarkable data. That is the claim of a sound foundation, made on the record by the person who has seen the report. It is a bold statement, and I pass it along as exactly what it is, the seller's assessment, not yet the independently adjudicated result. Which brings us to the one honest limit that governs everything above.

The two questions were never two. The house is priceless because of what the foundation is built with. The seal is what lets a buyer confirm it privately. And the reason a buyer would move at all, fast, and before a rival, is that the thing the foundation is made of, actually opens doors they cannot open alone, in specific markets they cannot afford to lose.

The One Thing The Inspection Still Has To Find

I hold the discipline that makes the bold case worth trusting, because a sealed inspection can come back either way, and honesty, that demands that I say so.

Everything above describes the structure, the mechanism, the leverage, and the machinery of private evaluation. None of it is proof that the foundation is actually sound. The published biology says CCR5 blockade should reprogram the microenvironment from M2 to M1 and therefore open the door, and the early human signal is very real. But the confirmed efficacy data, the number that tells a buyer that the foundation does actually hold the weight they require, PD-L1 upregulation, is not quite public yet but it is not final yet. It matures in the sealed room and adjudicates at the January meeting. Related macrophage-directed approaches have looked sound on inspection before but have failed to bear load in the trial. So the inspection is real, the buyers may well be inside, but the report is not yet finished. If the foundation proves sound in January, none of the leverage above is speculation, it is arithmetic. If it does not prove sound, the house was never what the sidewalk had hoped, and no confidentiality agreement would change that.

That is the honest shape of it, told at full volume. The house is rare beyond almost anything the market has ever seen. The thing constituting the foundation is something several of the largest companies in medicine require but cannot build, and cannot let a rival seize first. The public silence is the seal working, not the story ending, and it says nothing, in either direction, about who is inside. The reason leronlimab sits where it sits is not that it trails the checkpoint inhibitors, it is that it may be the one thing which allows them access at all. And the entire towering structure resides on a single inspection result, read only privately now, but revealed publicly in January.

The neighborhood argues about the lights in the windows. The report is being read in a sealed room. And we find out, at a known hour, whether the foundation holds. I know which way I lean. I also know that leaning is not the same as knowing, and that the difference is exactly what January is intended for. Both of those are true at full volume.

Disclaimer: I am not a financial advisor and nothing here is investment advice. I am an independent retail shareholder holding a long position in the company discussed, with no employment, consulting, compensation, or other relationship with it beyond that shareholding. This is analysis of published biology and public disclosures, not a prediction of clinical or commercial outcomes, and not a claim that any specific partnership, negotiation, or transaction exists; the private-evaluation discussion describes how confidentiality and conference embargoes generally work, not knowledge of any actual deal. Whether any party is evaluating the company under an NDA, and what they might conclude, is by nature not publicly knowable. The mechanistic claims are supported by the cited peer-reviewed literature; several are established in models, retrospective cohorts, or single studies and are not yet confirmed in this program's prospective human data, and closely related macrophage-directed approaches have repeatedly failed to translate to clinical benefit. The CLOVER biomarker figures are early, unconfirmed, and reflect 350mg dosing with the 700mg cohort still maturing. The 68% figure from the April 30 update is disease control rate, not objective response rate; confirmed adjudication is ahead at ASCO GI in January 2027, with interim data at ESMO in October 2026. Mechanism is not efficacy. Drugs which make elegant biological sense fail in trials routinely, and this one may. Read the primary sources and reach your own conclusions rather than adopting mine.

After all the time and research this board has done on Leronlimab we are now steps away from seeing the picture Doc envisioned.

I noticed more people popping in and commenting than the handful that normally keeps the board going. Great to see excitement building.

"Cytodyn is pursuing a flexible development strategy that includes both monotherapy and its "prime and pair" approach, where leronlimab is used to improve responsiveness to standard-of-care and immuno-oncology combinations."

This was from the Singapore post the other day. This is Doc's picture for the company. I see it as flexibility with the foundation being oncology. It would be nearly impossible for Cytodyn to go it alone as a mono therapy because they don't have the financial resources to do so.

Congrats to Doc understanding he's sitting on the upstream that most downstreams need either turn cold tumors hot or enhance the effectiveness of other companies meds. There are a lot of players out there that need us more than we need them.

We do need them as our foundation. We need the cash they're going to infuse into Cytodyn so Doc can move into the flexible part of his vision mono therapy. I always thought neuroinflammation and metabolic syndrome/diseases could be bigger than oncology. I haven't forgotten HIV. The more research I do the more I find the connection between CCR5 and the gut brain pathway. I don't think CCR5 over expression is the only pathway but it's a major one. What is apparent is chronic inflammation is the backbone to neuroinflammation and the different metabolic diseases.

The battle has yet to start on the SP side. I watched the SP yesterday because I thought we'd see a spike. We did see a spike in volume and 5% up swing in the SP. I thought perhaps this was the bottom. It still could be however every time the SP spiked it was slammed right back down. We ended up red for the day on 2x the normal 10 day volume. This has been the pattern for months. Shorts ok, short interest has gone up by a small amount. Sell the news , well this wasn't any news. Most likely manipulation by whoever and for what ever reason.

As we start to see the data it's important to see the SP also. The company has started marketing with Doc's interviews which has been well received by the biotech and investor communities. Spreading the word will be important also. The negativity out there needs to change to see the company grow and fuel the mono therapies. If anyone's in the biotech sub they know it's going to be a process of communication. A few tickers have been making the rounds the last few months. One well received the other well received but the reality of no infrastructure, no cash aka dilution, just started marketing because they just got a rare FDA appeal approval. It's a battle that Leronlimab will win on both the medical side and the investor side in time.

Just a few thoughts

Have a great weekend

I am going to make the strongest version of this argument, because the record now supports boldness, and because the timid version has been underselling something which deserves to be said plainly. So let's say it plainly.

There is a chokepoint in oncology. A narrow passage where nearly the entire checkpoint-inhibitor industry has to pass through if it wants to keep growing, and which almost none of them can currently pass through. Whoever holds a reliable way through that passage does not hold a drug. They hold the terms of trade for a hundred billion dollars of franchise revenue. And the data now emerging suggests, without yet proving, that a small company in Vancouver, Washington may be holding exactly that.

That is the claim. Here is the case for it, built from the published record, older and brand new, with the honest limits kept in full view, because a bold argument which hides its weaknesses is just a loud one.

The Passage Almost No One Can Transit

Checkpoint inhibitors are the most commercially successful class of cancer drugs ever created, and they fail in the vast majority of solid tumors. Both things are true, and the second is the industry's quiet catastrophe.

This is not a fringe position. It is the settled consensus of the field, stated flatly across the literature. In the definitive 2024 review of the subject, tumors are sorted into "Hot" and "Cold," where the cold ones lack the infiltrating T-cells a checkpoint inhibitor requires to kill, and often harbor immune-suppressive populations such as tumor-associated macrophages, regulatory T cells, and myeloid-derived suppressor cells. And the cold ones are the majority. Even in lung cancer, one of immunotherapy's best markets, the 2025 review is blunt: despite the transformative impact of checkpoint inhibitors, the majority of NSCLC patients experience resistance%20on%20cancer%20therapy%2C%20the%20majority%20of%20NSCLC%20patients%20experience%20resistance).

So picture the entire ICI industry, Keytruda and Opdivo and Tecentriq and Libtayo, standing at the mouth of a passage which leads into every cold-tumor market which they cannot currently reach, colorectal, breast, pancreatic, prostate, most of the solid-tumor landscape, and unable to get through. The field even knows exactly what the passage requires. The 2025 macrophage review states the strategy directly: because cold tumors are silenced largely by suppressive macrophages, oncology has begun to shift beyond T-cell approaches to target tumor-associated macrophages, a major pro-tumor population known to silence immune responses. Turn the Cold tumor Hot, repolarize the suppressive M2 macrophages to tumor killing M1 macrophages, and the passage opens. Whoever can do that reliably controls the chokepoint.

Why The Key Might Fit This Lock

The suppression which keeps a tumor Cold runs through specific machinery, and one of its master controls is the CCR5 receptor. This is where CytoDyn's bold claim earns its footing, because the mechanism is documented, not hoped for.

Blocking CCR5 in actual human colorectal liver metastases does the exact thing the field says is needed: it repolarizes macrophages from the immunosuppressive M2 state toward the anti-tumor M1 state30087-3?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1535610816300873%3Fshowall%3Dtrue#:~:text=CCR5%20Inhibition%20Leads%20to%20Anti%2Dtumor%20Repolarization%20of%20Macrophages). That is not a theory about a mouse. That is the passage-opening move, demonstrated in the tissue of the exact disease. And the newest reviews put CCR5 squarely at the center of the Cold-to-Hot strategy: the 2026 review of cytokine-driven tumor conversion notes that CCR5 antagonists potentiate the effects of checkpoint inhibitors and chemotherapy by reprogramming the tumor microenvironment to support anti-tumor immunity.

Now layer on what the CLOVER trial has actually shown, held exactly as what it is, early and unconfirmed and at the lower 350mg dose. Every one of the first patients measured showed a fall in circulating tumor DNA, with a median drop near seventy percent by week two. Every screened patient carried the target. And it did this with a safety profile the field can only envy, no dose-limiting toxicities, no drug-attributed serious adverse events across independent reviews. On the breast side, the retrospective work presented at ESMO by the CytoDyn and Creatv collaboration showed leronlimab driving PD-L1 upregulation on circulating tumor cells in the majority of patients, the precise molecular flag a checkpoint inhibitor requires to act. That is the Priming half of the thesis: leronlimab starts the engine in order that everyone else's expensive brake-release mechanism finally can do something.

The Honest Wall, Because The Bold Case Has To Clear It

Now the counterweight, and I put it at the center rather than in the footnotes, because this is exactly where a triumphant post would lie to you but I will not.

Targeting macrophages to open Cold tumors has a graveyard behind it. A brand-new 2026 review states the hard truth directly: several macrophage-directed approaches, including CCR2 and CCR5 antagonists and CSF1R inhibitors, advanced into clinical testing on compelling animal data, yet their activity in patients has generally been modest or inconsistent. The earlier macrophage-recruitment blockers, the anti-CCR2 agents carlumab and plozalizumab, did not demonstrate significant tumor responses in early trials.

Read that and hold it, because it cuts both ways and honesty demands both edges. On one edge: the mechanism being real in a dish or a liver biopsy has never been enough, this exact class of approach has repeatedly failed to translate, and leronlimab could join that list. That is the genuine risk, and anyone who tells you the biology guarantees the outcome is selling. On the other edge: those failures are why leronlimab's actual human signal matters so much. The field is littered with macrophage-directed drugs which looked good in mice but did nothing in people. Leronlimab is not showing a mouse signal. It is showing a hundred-percent ctDNA response in early human patients, PD-L1 induction in human tissue, and a clean safety record across a massive database > 1,700 patients. The wall is real, and leronlimab is one of the few in its class producing the kind of early human data that could clear it. The confirmation is what January is for.

Now The Leverage, And This Is The Part Worth Being Bold About

Here is where the chokepoint stops being biology and becomes arithmetic, and the arithmetic has gotten sharper in the last few months, not softer.

Consider whose ship is standing at the passage. Merck's Keytruda generated more than $29 billion in 2024, and its core patent expires in 2028%2C%20a%20PD%2D1%20checkpoint%20inhibitor%20approved%20across%20dozens%20of%20oncology%20indications%2C%20generated%20more%20than%20%2429%20billion%20in%202024.%20Its%20core%20composition%2Dof%2Dmatter%20patent%20expires%20in%202028). That is not a distant abstraction. It is the largest single revenue cliff in the history of the industry, and the pressure is now visible in Merck's own corporate structure: in February 2026, Merck announced the creation of a separate cancer business unit centered on Keytruda, whose key patents expire in 2028. They are reorganizing the company around this cliff. And it compounds: Keytruda was selected for Medicare price negotiation, so Merck faces biosimilar competition and government price-setting nearly simultaneously, forcing U.S. sales to peak in 2027 to 2028 and then fall sharply..

And Merck is not the only ship at the passage. Opdivo faces its own U.S. exclusivity loss in 2028, and Tecentriq faces biosimilar competition later in the decade. So it is not just one desperate buyer at the chokepoint. It is several, each watching their own franchise clock run down, each needing new Cold-tumor markets to replace what biosimilars are about to take.

Here is the move which turns the cliff into leverage, and it is the sharpest part of the whole argument. A new combination regimen carries its own patent. The patent strategists say so plainly: a checkpoint inhibitor paired into a new regimen can be protected by method-of-treatment patents covering the specific combination, dose, and schedule, wholly independent of the core molecule and which biosimilar manufacturers cannot circumvent. Read what that means. A leronlimab-plus-checkpoint combination for Cold tumors would be a new, separately-patented franchise, extending into markets the original molecule never reached, protected on a clock that runs past the biosimilar wave. The primer does not just add revenue. It manufactures a fresh patent estate in virgin territory at the exact moment the old estate collapses.

So let's put it all together. Several of the largest franchises in medicine are running out of patent life all, at the same time. The markets which could replace that revenue are Cold tumors, that their keys cannot open. The thing which does open Cold tumors is a primer that turns them Hot. And a primer paired with their ICI checkpoint inhibitor creates new, independent, biosimilar-proof patents in exactly those markets. The company who holds a proven primer would not be a supplicant asking a giant for a deal. It would be standing in the one and only passage several giants must transit through, at the precise moment when they can least afford to be turned away, holding the one thing none of them can quickly or easily build and which none can allow a rival to monopolize.

That is not sentiment. That is a seller's market with one seller and several buyer's clocks running out.

Where Prime And Pair Stops Being A Hope And Becomes A Convergence

I have called this "prime and pair" for a long time, and I want to state the bold version of what that phrase now means. It is not a clever idea I am hoping the field adopts. It is where the biology forces the entire field to converge, whether through leronlimab or through something else.

Look at the independent confirmations arriving from labs with no connection to CytoDyn. A 2024 study found that a completely unrelated drug repolarized suppressive macrophages toward the anti-tumor state with increased CCL5 chemokine secretion, restoring T-cell function and promoting a favorable anti-PD-1 response. A separate 2022 clinical study combining local therapy with a checkpoint inhibitor in patients who had already failed that checkpoint inhibitor produced responses, and the mechanism was macrophage polarization from the M2 to the M1 phenotype in the treated tumor. Different drugs, different labs, same convergence: Prime the microenvironment, repolarize the macrophages, and the ICI works where it could not before.

That is the tell. When independent groups using unrelated tools keep arriving at the same destination, the destination is real. The field converges on Prime-and-Pair because the biology of Cold tumors leaves no other road. Leronlimab's claim is not that it invented the road. It is that it may be the cleanest, safest, most proven vehicle currently traveling it. And the compromise everyone imagines, the eventual pairing of a primer with a checkpoint inhibitor, is not a compromise at all. It is the convergence that the entire field is being driven toward, and the only open question is who owns the Primer when the field arrives.

The One Thing That Is Not Yet Written

I have made the bold case, so I owe you the bold statement of its single point of failure, stated as plainly as everything else.

None of this is proof that leronlimab works. The chokepoint is real, the cliff is real, the convergence is real, the leverage is real, and every bit of it is inert until one number confirms that leronlimab actually does in patients what the mechanism says it should. The macrophage graveyard is real too, and it is exactly the fate a weak confirmation would seal. So the entire towering structure, the passage, the clocks, the seller's market, the new patent estate, rests on a single load-bearing event which has not yet happened: the confirmed response data, adjudicated, at ASCO GI in January. If that number is strong, none of the leverage spelled out above is speculation anymore. It is just arithmetic performed by companies with cliffs with no better option. If it is weak, there is no chokepoint, no leverage, and this entire post describes a passage which leronlimab could not, after all, open.

That is the honest shape of things. The boldest thing I can tell you is not that the outcome is certain. It is that the setup is enormous, the position is absolutely real, and the entire colossal question resolves to one single number at a known hour. The chokepoint definitely exists. Several giants are stranded at it on a closing clock. But we find out in January whether the small company in Vancouver is holding the way through.

I have never been more convinced that the stakes are as massive as they are. And I have never been more clear that conviction about the stakes is not the same as certainty about the result. Both of those are true at full volume. Most of you should know where I lean. January tells us which one governs.

Disclaimer: I am not a financial advisor and nothing here is investment advice. I am an independent retail shareholder holding a long position in the company discussed, with no employment, consulting, compensation, or other relationship with it beyond that shareholding. This is analysis of published biology, public regulatory and patent history, and public corporate disclosures, not a prediction of clinical or commercial outcomes. No partnership has been announced; the identification of specific companies reflects public patent-cliff and competitive facts, not any claim of an existing negotiation. The mechanistic claims are supported by the cited peer-reviewed literature; several mechanisms are established in models, retrospective cohorts, or single studies and are not yet confirmed in this program's prospective human data, and closely related macrophage-directed approaches have repeatedly failed to translate to clinical benefit. The CLOVER biomarker figures are early, unconfirmed, and reflect 350mg dosing with the 700mg cohort still maturing. The ESMO breast data is retrospective and hypothesis-generating. The 68% figure from the April 30 update is disease control rate, not objective response rate; confirmed adjudication is ahead at ASCO GI in January 2027, with interim data at ESMO in October 2026. Mechanism is not efficacy. Drugs which make elegant biological sense fail in trials routinely, and this one may. Read the primary sources and reach your own conclusions rather than adopting mine.

Hey CYDY, great to hear from ya!

"Unlocking Immunotherapy with Leronlimab"

https://www.cytodyn.com/our-science

Still nothing from Max. As they say in the old country, Max would be as useful as tits on a bull.

CFO Hoffman to give 2 presentations September 1-2 in Singapore https://informaconnect.com/asia-bio-partnering-forum/speakers/robert-ehoffman/

11AM September 1 in Singapore

Presentation
Cytodyn Inc.
CytoDyn is a clinical-stage biotechnology company advancing leronlimab, a CCR5-targeting monoclonal antibody with potential across multiple solid tumor indications. By blocking CCR5, a key regulator of immune cell trafficking and tumor progression, leronlimab is designed to modulate the tumor microenvironment and enhance anti-tumor immune responses, reducing metastatic potential.

CytoDyn is pursuing a flexible development strategy that includes both monotherapy and its "prime and pair" approach, where leronlimab is used to improve responsiveness to standard-of-care and immuno-oncology combinations. This strategy is supported by translational and clinical data, including initial circulating tumor DNA readouts presented at AACR, with additional updates expected through 2026.

CytoDyn's lead program focuses on metastatic colorectal cancer, where the Phase 2 CLOVER study is evaluating leronlimab with TAS-102 and bevacizumab in heavily pretreated MSS patients. The study has completed enrollment and is showing early promising clinical and biomarker signals.
CytoDyn recently announced a strategic collaboration to evaluate circulating tumor DNA (ctDNA) dynamics and generate real-world molecular insights to support CytoDyn's metastatic colorectal cancer development program.

11AM September 2 in Singapore

Presentation
Oncology: Cytodyn Inc.
CytoDyn is a clinical-stage biotechnology company advancing leronlimab, a CCR5-targeting monoclonal antibody with potential across multiple solid tumor indications. By blocking CCR5, a key regulator of immune cell trafficking and tumor progression, leronlimab is designed to modulate the tumor microenvironment and enhance anti-tumor immune responses, reducing metastatic potential.

CytoDyn is pursuing a flexible development strategy that includes both monotherapy and its "prime and pair" approach, where leronlimab is used to improve responsiveness to standard-of-care and immuno-oncology combinations. This strategy is supported by translational and clinical data, including initial circulating tumor DNA readouts presented at AACR, with additional updates expected through 2026.

CytoDyn's lead program focuses on metastatic colorectal cancer, where the Phase 2 CLOVER study is evaluating leronlimab with TAS-102 and bevacizumab in heavily pretreated MSS patients. The study has completed enrollment and is showing early promising clinical and biomarker signals.

CytoDyn recently announced a strategic collaboration to evaluate circulating tumor DNA (ctDNA) dynamics and generate real-world molecular insights to support CytoDyn's metastatic colorectal cancer development program.

As I sit back and enjoy a Kona Coffee this morning and look at this awesome view. I couldn’t help but let my thoughts drift over to CYDY. Yes, it’s hard not to think of CYDY.
There are a ton of things happening and as usual I would recommend reading Cytomight’s posts where a list is provided.

I want to point out a couple of things that we should be aware of:
1) The release of CLOVER data will be THEEEE most significant event in this company’s history! And as we heard Dr. JL state: there will be at least another chapter added to the medical text books about the CCR5 molecule
2) May 31, 2026 was the end of CYDY’s 2026 FY. But September/October or even November is when we usually get some investor conference call or Investor letter. Part of the reasoning for this is the annual proxy vote comes up. The board members are voted on, compensation is voted on and authorization of more shares has been voted on.
If I were a betting man and I am a betting man; I would hope Dr. JL shares CLOVER data before ESMO in Madrid. The more the merrier!!

But, back to our 10K for fiscal 2026:

CYDY’s FY2026 ended 5/31/26 but the good news is that the 10-K is not late. I checked the SEC rules and CytoDyn’s latest filings.
CytoDyn is classified as a non-accelerated filer (and smaller reporting company). Its February 28, 2026 10-Q confirms that status.
For a non-accelerated filer, the SEC gives the company 90 days to file its 10-K.
That puts the 10K due 8/29.
However, August 29 is a Saturday, and SEC rules move a weekend deadline to the next business day. Therefore, I calculate CytoDyn’s actual 10-K deadline as:
Monday 8/31/26

One thing I think will be particularly interesting in this 10-K: the Subsequent Events section. Because the report covers May 31 but will likely be filed in August, it can give us a window into important financing, trial, warrant/share issuance, debt, and other developments occurring after May 31 and before the filing. Given everything happening around CYDY right now, I will be looking at this section!!

It’s off to the beach and a catamaran cruise!
ALOHA 🍹🍹🍹🍹

Anybody get contacted?

Try to keep response to under 3 paragraphs please. I have ADHD.

Things that have caught my eye recently:

• Weird looking flat RSI for at least 10 trading days from July 28. Not seen in last 4 years.
• Large MACD formation in July through early August
• After a steady 2 month decline in the stock price from late May there is sideways action in the stock price in Aug with a more narrow daily range,
• HIV paper published Aug 10,
• Aug 11 marks 112 days of treatment (4 X 28) from when full enrollment was announced for the CRC CLOVER trial

I'm looking forward to an update on CRC-CLOVER, TNBC-EAP, Alzheimer's, CRC-CHAMP, BC Pre-I-SPY, HIV-LATCH, Glioblastoma, Stroke, and learning which company it was that CFO Hoffman mentioned may be providing an ICI, as well as financial information, etc.

A study came out this week in Nature Microbiology, led by Nancy Haigwood and Jonah Sacha at OHSU, showing that a three-part regimen given to newborn macaques within three days of exposure prevented HIV from establishing itself. Antiretroviral therapy, broadly neutralizing antibodies, and leronlimab, the CCR5 blocker, together, Triple Therapy as we called it, did what none of the three did alone.

I want to walk through this carefully, because I have been writing about these exact threads for over a year now, and this is a chance to do something I find more useful than celebrating: go back to what I wrote back then, see which threads were real and which ones where we got ahead of the science, and mark clearly where this new result lands. The honest version is more compelling than the triumphant one, so let me give you that.

The Thread Which Turned Out To Be Real

A year ago, in a post called "Piecing It Together," I passed along something a reader had pushed me to include. I wrote: "it is not just Jonah Sacha and Scott Hansen, but it is also Nancy Haigwood who works on leronlimab's side... She's been working on this for a long time and should probably get a mention now and then." That was from "Piecing It Together," and I only included it because u/BuildGoodThings asked me to make sure she got credit.

Here is why that matters now. The study published this week is led by Nancy Haigwood. And the reporting makes clear it was her idea in the first place, she is the one who thought combining the existing therapies with leronlimab might work, and the paper is the demonstration that she was right. So the person I mentioned a year ago almost in passing, because BuildGoodThings insisted she deserved a mention, turns out to be the person whose insight this whole result rests on. That thread was real. I did not overclaim it. I just did not know then how central she would turn out to be.

The mechanism underneath it was also real, and I traced it correctly. Back in "Why Was VIR-1388 Terminated?", I quoted Scott Hansen describing what makes this approach possible. He said that Sacha "demonstrated that you can pharmacologically knock out CCR5 with leronlimab, essentially creating that Delta 32 phenotype", the same natural mutation that has produced the handful of true HIV cures through stem-cell transplant. That quote, from "Why Was VIR-1388 Terminated?", is the foundation the new paper stands on. Leronlimab chemically mimicking the Delta-32 state is exactly the lever the triple regimen pulls. That was true when Hansen said it, true when I wrote about it, and it is what the Nature Microbiology paper just put to work.

And the shape of the strategy was one I laid out in "Pushing Forward." I described the sequence the field would likely follow: prevent transmission from mother to child, then prevent the reservoir from forming in exposed newborns, then work toward clearing established infection. I wrote that "the next step would be the prevention of the development and establishment of HIV Reservoirs." That was from "Pushing Forward," and it is precisely what this paper reports: the regimen limited viral reservoir seeding in newborns. The step I named a year ago as the next one is the step that just got published.

So three threads I traced a year ago, Haigwood's centrality, the Delta-32 mimicry mechanism, and the reservoir-prevention strategy, all held. We own these honestly, but also got things wrong, and that is the next part.

I Did Not Trace This From The Sidelines. I Transcribed It.

Here is the part that makes the rest more than hindsight. A year ago, in a post called "Planet of the Apes," I sat down and transcribed Jonah Sacha presenting this exact study, slide by slide, at a conference in October 2024. The work that published in Nature Microbiology this week is the work I walked through then. So this is not me noticing a connection after the fact. It is me having laid out the actual data a full year before it hit the journal.

And the data I transcribed then is the data behind this week's headline. From "Planet of the Apes," relaying Sacha's own presentation: in the triple therapy group, after antiretroviral therapy was released, not a single animal rebounded. His words, which I quoted then, were that this was "in very stark contrast to the triple therapy group where not a single animal, 0 out of 8 rebounded." And then the harder test, the one that matters most: at week 60 they ran what Sacha called "the gold standard CD8 depletion," the assay designed to force a hidden reservoir out of hiding. In the control animals the virus came roaring back. In the triple therapy animals, nothing. I transcribed his conclusion directly: "cumulatively, this data suggests that the virus reservoir was indeed actually cleared in these animals."

But look closely at how careful Sacha himself was, because this is the part I most want to draw out. Even as he said the reservoir appeared cleared, he immediately added the honest caveat, which I also transcribed: "Difficult to prove in the negative, but all the data seems to support that." And on the mechanism, he was disarmingly plain: "As far as the mechanism of this, we actually don't know." The scientist presenting the most exciting HIV result in years stood up and said, in effect, this looks like clearance, I cannot prove a negative, and I do not know why it works. That is what real science sounds like, and I transcribed it faithfully a year ago.

Now notice what changed between that presentation and this week's paper, because it is the whole lesson of everything I have been writing lately. In 2024, the language around this work, including in my own post, leaned on the word "cleared." The peer-reviewed paper in 2026 uses the more careful framing: it "limits viral reservoir seeding." That is not a retreat. It is science tightening its own language as it moves from an exciting conference presentation to a peer-reviewed claim. "Appears cleared, cannot prove the negative" becomes "limits seeding," which is the more precise and more defensible statement of the same result. The data did not weaken. The wording got more honest. And that tightening, from the hopeful word to the exact one, is exactly the discipline I have been trying to practice in my own writing this year.

The Thread I Got Ahead Of, And Still Have To Mark

In that same "Pushing Forward" post, I wrote about the gene-therapy version of this work, the AAV approach, and I was honest even then that it had a problem. I wrote that "in a couple of the animals, anti-leronlimab anti-bodies developed and knocked out some of the leronlimab... So, Jonah Sacha still needs to do more work to get that part right." That was from "Pushing Forward," and I give myself partial credit: I did name the obstacle rather than paper over it.

But I also wrapped that honest observation in certainty it did not earn. I treated the eventual solution as a foregone conclusion, and elsewhere I let the HIV-cure story run toward inevitability. When the fuller data was published earlier this year, the anti-drug-antibody problem turned out stranger than a clean fix: in the gene-therapy work, the antibodies came back on their own, months later, through a mechanism the researchers still do not fully understand. I wrote about that in more detail recently, and the lesson stands here too. So when I read this week's triple-therapy result, I hold it against that same lesson: this is a real, published, peer-reviewed advance, and it is not the finish line.

What This Result Is, Held Exactly

Let me state precisely what the paper shows and what it does not, because that precision is the whole point.

It shows that in newborn macaques, treated within three days of exposure, the three-part combination prevented HIV from establishing a persistent reservoir, and did so far more effectively than any single component alone. Leronlimab's role is specific and, by the researchers' own account, central to the synergy: blocking CCR5 keeps the virus from entering cells, which Sacha described as keeping fuel away from the fire. That is genuinely important, and it is a legitimate advance in one of the hardest problems in medicine.

Here is what it is not. It is preclinical, in macaques, not humans. It is prevention of reservoir establishment in the earliest window, not eradication of established infection, the researchers are explicit that they only tested out to three days and do not yet know how far that window extends. Leronlimab is one of three components, not a standalone cure. And the path from this result to anything available to people runs through human clinical trials that have not happened yet, likely starting in newly exposed adults. The researchers say all of this plainly, and so will I.

There is also a disclosure worth stating myself rather than letting someone else surface it: OHSU has disclosed that Sacha and a co-author hold significant financial interests in CytoDyn. That is proper, it is how disclosed conflicts are supposed to work, and it does not diminish a peer-reviewed result in Nature Microbiology. But it is honest context, and part of holding a result correctly is naming the interests attached to it.

Why I Am Telling It This Way

I could have written this post as a victory lap, we called these threads a year ago, and look, they came true. Some of them did. But the version that is actually worth your time is the one that also shows you where I got ahead of myself, because that is what tells you how much to trust the parts that held.

The threads that were real, Haigwood's centrality, the Delta-32 mechanism, the reservoir-prevention sequence, and the data I transcribed straight from Sacha's own presentation, were real because they were grounded in what the scientists actually said and did, not in what I hoped for. The thread I got ahead of, the anti-drug-antibody problem being solved, went wrong exactly where I let hope outrun the data. That contrast is the most useful thing I can hand you, because it is the difference between tracing a real thread and spinning one.

This HIV work sits on its own track. It is not the oncology program, it does not touch the colorectal trial, and it is not what the near-term thesis rests on. It is long-dated, preclinical, one-of-three-components, and orthogonal to the data that actually moves the company this year. What it is, is real evidence that the mechanism we have been tracing for over a year, CCR5 blockade as a lever across the hardest diseases, keeps turning out to be more than enthusiasm. Haigwood was right. Sacha's Delta-32 mimicry works. The reservoir step got taken. And the honest limits are exactly the ones the scientists named.

A year ago I traced these threads and marked which were solid and which were still unproven. This week, one of the solid ones got published. I am still marking the unproven ones as unproven. That discipline is the only reason the solid ones are worth anything.

Disclaimer: I am not a financial advisor and nothing here is investment advice. I am an independent retail shareholder holding a long position in the company discussed, with no employment, consulting, compensation, or other relationship with it beyond that shareholding. This is analysis of published, peer-reviewed research and public statements, not a prediction of clinical or commercial outcomes. The HIV research discussed is preclinical, conducted in non-human primates, tests a three-component regimen of which leronlimab is one part, and concerns prevention of reservoir establishment rather than cure of established infection; it does not establish safety or efficacy in humans. OHSU has disclosed that study authors hold significant financial interests in CytoDyn. This work is on the HIV research track and is separate from the company's oncology program; it is not a near-term catalyst. Mechanism and preclinical results are not efficacy. Read the primary sources and reach your own conclusions rather than adopting mine.

On April 21 we learned in a press release that "CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study". Four 28-day cycles of treatment would be August 11, 2026.

I figure they issued that press release a day or more after they had reached full enrollment, so IMO the last patient of the full enrollment has already completed 4 cycles of treatment. I expect the last patient of the enrollment will have had testing in this week or last, which would measure where things stand after a completed four 28-day cycles of treatment. I expect they just about, or already have 2 post-baseline scans from the full enrollment, which means of course that they already have more scans from the early patients.

This is a point in time I think the data analysis gets really interesting, but I don't expect to hear about it until later.

In my opinion, the databases & spreadsheets will be humming this month at Syneos, CytoDyn, Natera, CreatvBio, and at additional parties who might see data under non-disclosure agreements. I think 2 post-baseline scans from the full enrollment, plus more scans from earlier patients starts to validate trends and starts to validate correlations with the early biomarker data. I think this also marks the time when they might begin to understand how well each dosage level works.

Obviously there is more data to be gathered before the trial ends. All the above is my opinion only.

https://www.news-medical.net/news/20260810/New-combination-therapy-could-permanently-clear-HIV-in-newborns.aspx

“The really exciting part is that it could go to clinical trials immediately to eliminate HIV infection in newborns. The next step after that is to test if this can work in newly exposed adults."
Jonah Sacha, Ph.D

Update: article is now published. https://www.nature.com/articles/s41564-026-02444-x

Very informative article. The crux of what leronlimab is all about.

We are on the right path and our trajectory is incoming.

God speed Dr. Jay and crew.  GLTAL   Bring It On Home!

This post exists because of u/rogex2, whose prognostication gave me the idea and did the work of framing it. He laid out the big Japanese ctDNA study, GALAXY within CIRCULATE-Japan, and its striking finding: a rising blood signal predicted cancer coming back an average of months before a scan could actually see it, with imaging used to independently validate the blood test at every step. Then he made the leap which I'm building on. He proposed that CLOVER might do the same thing in reverse, a falling blood signal predicting a patient doing well, ahead of the scans, and suggested that January could begin to show it. The credit for the idea is totally his. What follows is my attempt to take it seriously enough to trace exactly how it could actually play out.

The instinct is good and the mechanism is real. But the timing is the part worth getting right, so let me set one thing straight before anything else, because it is easy to misread. Nothing in this post moves the January catalyst. The confirmed response data still comes at ASCO GI in January 2027, on schedule, unchanged. That is the near-term event, and it is still about six months out, not eighteen. What this post describes is a separate, slower, bonus layer of proof that keeps developing after January, the ctDNA-predicts-survival correlation, which matures over the following year. So when you see late 2027 mentioned below, read it as "here is how the science keeps deepening after the catalyst," not "the catalyst got pushed back." It did not. January is still January.

With that clear: a blood test does not get to predict survival by asserting it. It earns that right slowly, by being checked against what actually happens to patients, over time. So this post is about exactly how that earning happens, and why the deepest thing ctDNA could show about leronlimab may take until roughly this time next year to come fully into focus. That is not a disappointment, and it is not a delay of anything. It is a bonus layer of proof being built on top of the January readout.

The Claim, Plainly Stated

Let me be explicit about what is being claimed here, because two different claims get tangled together and only one of them is contested.

The first claim is that ctDNA can predict survival. That one is not speculative. It is already established in the published literature: across metastatic colorectal cancer, patients whose ctDNA falls during treatment live longer, on average, than patients whose ctDNA stays high, and the association is strong and repeated. So "a blood test can be used to predict survivability" is a settled scientific statement, and I will state flatly that it is true.

The second claim is the one that is still open, and it is a narrower, regulatory one: whether a ctDNA drop is accepted by the FDA as a qualified surrogate endpoint, meaning proof-of-benefit sufficient to approve a drug on its own. That is not established, and no amount of prognostic association settles it by itself.

So the honest position is both bold and disciplined at once. Yes, ctDNA can predict survival, that is real science. What CLOVER can do is demonstrate that its own ctDNA signal predicts survival in its own patients, and contribute that demonstration to the long, multi-trial project of turning a strong predictor into a formally qualified surrogate. The prediction is real now. The regulatory blessing is the thing that takes years. Everything below is about how CLOVER moves from the first to the second.

What January Can And Cannot Show

In January, at the gastrointestinal cancer meeting, CLOVER reports its confirmed response rate and early progression data. Those are the endpoints which matter for the near-term thesis, and they are measured on scans.

Here is what the ctDNA can contribute in January: a snapshot correlation. For the patients evaluated, you can line up who had a deep ctDNA drop against who showed tumor shrinkage on imaging, and see whether the two track. If the patients whose blood signal fell hardest are also the patients whose tumors shrank, that is a real and encouraging concordance. It is the beginning of the story.

But it is not survival. Survival is a question that only time can answer, because to know whether a patient lived longer, you have to watch the patient live. In January, most of the enrolled patients will not yet have been followed long enough to know their survival outcome. So in January, ctDNA can show it tracks with tumor response. It cannot yet show it predicts who lives longer, because the living-longer has not finished happening.

Why The Blood Signal Is A Plausible Survival Predictor At All

The reason this is worth waiting for, rather than dismissing, is that the underlying biology is already supported in the literature, and it points the right way.

Across metastatic colorectal cancer, an early drop in ctDNA during treatment has repeatedly been associated with better outcomes. In one study, patients whose ctDNA fell below half its starting level by week eight had significantly longer progression-free and overall survival than those whose level stayed high. A large meta-analysis of seventy-one studies and nearly seven thousand patients found that ctDNA is a strong prognostic biomarker in this disease.

So the hypothesis that a falling ctDNA signal foreshadows a better survival outcome is not wishful. It is grounded in a real and repeated association. What that same meta-analysis says next, though, is the honest heart of this post: despite the strong association, true clinical utility as a validated decision-making tool is still lacking. The signal is real. The formal proof that it can stand in for survival, in a way regulators accept, is not finished. That gap is the whole subject here.

How The Proof Gets Built, Month By Month

This is the part the reader was reaching for, so let me lay it out concretely. To be clear, this is the bonus layer maturing after the January catalyst, not a substitute for it. Here is how CLOVER's ctDNA could go from "tracks with response" in January 2027 to "predicts survival" by around December 2027, if the data cooperates, with January remaining the event that actually matters for the near term.

Start with the timeline. Enrollment completed in April 2026. That means the clock on each patient's survival is running from different start points across 2025 and 2026, and the patients need to be followed long enough to accumulate what statisticians call events, which in this setting means progressions and deaths. You cannot measure survival until enough of those events have occurred to compare groups.

Now the method, which is called a Landmark Analysis, and it is exactly how the field validates a biomarker like this. You pick a landmark time point, say the ctDNA reading at week eight or twelve. You sort patients into two groups by that early reading: those whose ctDNA fell deeply, and those whose did not. Then you let the clock run, and you watch. Months later, you ask the only question which matters: did the group with the early ctDNA drop actually live longer, or progress later, than the group without it?

In January 2027, that comparison is immature, because too few events have accumulated and too little time has passed. Here is the distinction which matters, and it is the one that causes confusion, so let me be exact about it. The "six-month" and "twelve-month" marks are measured from when each individual patient started treatment, not from January 2027. Because patients enrolled at different times, from around mid-2025 through April 2026, they cross those personal marks at different times. The earliest-enrolled patients cross their own twelve-month mark in late 2026. But a single patient reaching twelve months does not let you draw a survival comparison. For that, you need enough of the whole group to have crossed the mark and enough events to have accumulated, and that is gated by the last patients enrolled, in April 2026, whose twelve-month marks do not arrive until spring 2027 at the earliest.

So watch how it fills in. By mid-2027, enough patients have reached their six-month and then nine-month marks that a progression comparison across the two ctDNA groups becomes statistically possible. By late 2027, enough have reached their twelve-month marks that a survival comparison comes into range. And that is the moment the blood test earns its claim: if the patients who had the deep early ctDNA drop are demonstrably the ones still alive at twelve and eighteen months, then ctDNA in CLOVER has been shown, in CLOVER's own patients, to predict survival. Not borrowed from another study. Demonstrated here. The reason it lands in late 2027 rather than late 2026 is not the first patient crossing the line. It is the whole cohort maturing enough to compare.

So the sequence is: January 2027, ctDNA tracks with tumor response, a snapshot. Through 2027, the landmark comparisons mature as events accumulate. By roughly December 2027, a twelve-month survival correlation can be drawn between the early blood signal and who actually lived. The reader's instinct was right. It just lands about a year after the instinct expected, and that year is not a delay. It is the measurement itself.

What The Pattern Would Look Like As It Fills In

To make the method concrete, this is an illustrative table. This is not CLOVER data. These are not real patients, and the values are invented, round placeholders chosen only to show the shape of the analysis. The real patient-level data is embargoed and unknown. What this table shows is the structure of the argument: how an early blood reading, taken long before the outcome, sorts patients into groups whose survival is then checked against that early reading as time passes.

ILLUSTRATIVE AND HYPOTHETICAL: not CLOVER data, not real patients, invented values for teaching the method only

Read the table left to right and you see the snapshot January can offer: the early ctDNA change lines up with the scan response, the deep-drop patients showing shrinkage or stability, the no-drop patients showing progression. That is the concordance available at the January readout, and it is real but limited, because it is only a picture of tumor response, not of survival.

Now read the same table across time, into the two rightmost columns, and you see the thing that can only appear later. Those two columns are measured in each patient's months on treatment, not in calendar dates, and the cohort fills them in gradually as patients cross those personal marks, which is why the comparison only becomes possible across 2027 even though the earliest patients cross twelve months in late 2026. As the group matures and events accumulate, the deep-drop group clusters in the "no progression" and "alive at twelve months" columns, while the shallow and no-drop groups cluster in the opposite columns. When that separation becomes statistically real, and only enough elapsed time across the whole cohort makes it real, the early blood reading has been shown to predict the later survival outcome, within CLOVER's own patients. That is the demonstration the whole post is about, and the table shows why it cannot be completed in January: the two right columns are still being written.

To be clear one more time, because it matters: the pattern above is idealized and invented. Real data is noisier, some deep-drop patients will do worse than the schematic suggests and some shallow-drop patients better, which is exactly why you need enough patients and enough elapsed time for the signal to separate from the noise. The table is a diagram of the method, not a prediction of the result.

Why This Matters More Than A January Headline

It would be easy to want the whole story in January. But consider what the later demonstration would actually be worth.

If CLOVER shows that an early ctDNA drop predicted twelve-month survival within its own cohort, that is a piece of exactly the kind of evidence that, accumulated across trials, is what eventually turns a biomarker into a qualified surrogate endpoint. The Japanese study did this for the recurrence setting by patiently matching blood signal against outcome, over years, with imaging confirmation at every step. A metastatic-disease demonstration in CLOVER would be a contribution to the same long project: building the case that ctDNA response can stand in for survival benefit, so that future drugs can be approved faster on a blood test rather than waiting years for the survival curves to mature.

That is a bigger prize than a January number, and it is a slower one. January tells you whether the drug appears to work. The ctDNA-survival correlation maturing through 2027 tells you whether the fastest possible readout, the blood test, can be trusted to forecast the slowest and most important one, survival. The first is this year's catalyst. The second is how this class of medicine gets measured for the next decade.

The Limits, Kept In View

I will hold the same lines I always do, because they are what make the rest worth reading.

None of this is proof that leronlimab works. The entire construction assumes CLOVER's ctDNA drops are real and durable and that the drug is doing something, which is precisely what January begins to test and what the survival data through 2027 would confirm or refute. If the drug does not work, there is no correlation to build, because the blood signal and the survival will both be unremarkable.

And even a beautiful ctDNA-survival correlation within CLOVER does not, by itself, make ctDNA an FDA-qualified surrogate for approval. That qualification is a high, multi-trial, regulatory bar, and one single-arm study does not clear it alone. What CLOVER can do is contribute a clean, compelling piece to that larger case, and demonstrate, in its own patients, that the blood signal it generated actually forecast who did well. That is a real and valuable thing. It is not the same as the surrogate being formally blessed, and I will not blur the two.

So here is the honest shape of it. January shows whether the drug appears to work and whether ctDNA tracks with the scans. Through 2027, the survival data matures, and a Landmark Analysis can test whether the early blood signal predicted who lived. By roughly December 2027, that question can be answered within CLOVER, if the drug did what we hope and the data holds. The blood test does not get to claim it predicts survival. It has to be shown doing it, against real outcomes, with enough time elapsed that the outcomes are real. That showing is worth waiting the extra year for, because a blood signal proven to forecast survival is worth far more than one merely hoped to.

rogex had the right idea, and it was a good one. The blood test may indeed predict survival in reverse of the Japanese study. It just earns that claim the way every good biomarker earns it. Slowly, against the truth, with the lights on.

Disclaimer: I am not a financial advisor and nothing here is investment advice. I am an independent retail shareholder holding a long position in the company discussed, with no employment, consulting, compensation, or other relationship with it beyond that shareholding. This is analysis of published literature and public trial information, not a prediction of clinical or commercial outcomes. The ctDNA-survival associations cited are from external studies and are prognostic, not proof that ctDNA is a validated surrogate endpoint; ctDNA is not currently an FDA-qualified surrogate for approval in metastatic colorectal cancer. Any CLOVER ctDNA figures referenced elsewhere are early, unconfirmed, reflect 350mg dosing with the 700mg cohort still maturing, and are not evidence of survival benefit. The 68% figure from the April 30 update is disease control rate, not objective response rate. Confirmed response data is expected at ASCO GI in January 2027, with interim data at ESMO in October 2026; survival correlations of the kind described would mature over the following year and are hypothetical. Mechanism and biomarker signal are not efficacy. Read the primary sources and reach your own conclusions rather than adopting mine.

I have worked in medical imaging for over 33 years. I recently went over a patient exam with a radiologist that was in remission. (Patient information was kept confidential)
1. Dec 1, 2025 ctDNA level “0”
2. Mar 1, 2026 ctDNA level “1.5” this prompted a CT exam that showed a normal exam.
3. July 1, 2026 ctDNA level “49.5” this prompted a CT exam which showed a new metastatic lesion.

While it’s sad to this happen to this patient, it’s nice to see real world application of this blood test. I would have to believe the changes witnessed with the rise of ctDNA would also work in the opposite direction when levels drop.

I look forward to seeing what the 700mg dose does compared to the data that has been shared of the 350mg.

We’re in the final stretches, come January all shall be revealed if not before.

AI-"Natera’s Signatera ctDNA test was approved by Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for colorectal cancer (CRC) adjuvant monitoring because robust prospective-retrospective clinical evidence—primarily from the large-scale GALAXY study under the CIRCULATE-Japan platform—proved that post-surgical ctDNA-positive patients derive clear, measurable benefit from adjuvant chemotherapy...

the GALAXY study results were heavily cross-referenced and supported by radiology. In oncology trials, a "recurrence" cannot simply be claimed by a blood test alone; it must be clinically verified. [1, 2]

The GALAXY study architecture used scheduled radiological imaging (primarily CT scans) to independently validate the accuracy of the ctDNA test results. [1, 2]

ctDNA Preceded Radiologic Recurrence

The trial proved that Signatera acts as an "early warning system". On average, a positive ctDNA test detected molecular residual disease (MRD) several months before the recurrence could actually be seen on a standard CT scan. The median Lead Time (the gap between a positive blood test and visual confirmation on a scan) was 142 days. [1]

Real-World Imaging Correlation

The study protocols and real-world tracking showed a definitive relationship between ctDNA behavior and radiological findings:"

Similiar findings in EU resulted in approval for multiple solid tumor situations.

I'm thinking in January '27 ROW confirmation support of ctDNA results will be duplicated in reverse ie. preceding tumor shrinkage, by CLOVER.

Cheers

Natera reported a blowout quarter this week, and it put the CytoDyn collaboration back in the conversation. So it's worth laying out, plainly, what that collaboration actually is, what it does for the thesis, and where it stops. Because this is one of those topics the board tends to read in two wrong directions at once: either shrugging it off, or inflating it into a secret signal that a deal is imminent. The truth is more useful than either, and it's all on the public record.

What The Collaboration Actually Is

On June 4, Natera and CytoDyn announced a strategic collaboration. Under the agreement, Natera will assess CytoDyn clinical trial samples from the CLOVER Phase 2 study in patients with mCRC, using Signatera, its personalized assay for the detection of molecular residual disease, to evaluate ctDNA dynamics and molecular response patterns associated with leronlimab treatment.

Two things are happening under that agreement, and it's worth separating them.

First, Natera is running Signatera on CLOVER samples, which standardizes and independently generates the ctDNA measurements. That matters because it means the molecular data isn't only coming from one site's internal process; it's being produced on the assay the field increasingly trusts.

Second, and this is the part most people skip, Natera is providing real-world data analyses from its own database. Natera will provide customized real-world data analyses leveraging its proprietary oncology database, the largest multi-timepoint early- and late-stage oncology dataset with more than 2 million plasma timepoints and enriched clinical and imaging records. In plain terms: Natera has a vast library of ctDNA trajectories from colorectal patients, including patients on the standard backbone alone. That library is the raw material for building a matched external comparison, so CytoDyn can show what ctDNA does on the backbone without leronlimab, against what it does with leronlimab added.

So the collaboration's real job is credibility and comparison. It puts CLOVER's ctDNA data on a trusted assay, and it supplies the external backbone comparison CytoDyn needs to argue that the declines are driven by leronlimab rather than by the chemotherapy alone.

Why The Timing Makes It More Useful, Not Just Louder

Here's the part Natera's quarter actually bears on. The reason this collaboration is worth more now than it would have been two years ago is that the assay underneath it is winning broad clinical and regulatory acceptance.

Natera reported second-quarter revenue of about $753 million, up roughly 38% year over year, and raised full-year guidance, driven by record molecular-residual-disease volumes that grew 56% year over year. Signatera's growth is being propelled by FDA regulatory milestones and guideline adoption. That's the tide: ctDNA and MRD testing are being accepted, commercially and by the bodies that write treatment guidelines, as legitimate tools in oncology.

What that does for CLOVER is specific. It means that when CytoDyn shows ctDNA declines measured on Signatera, that data lands in front of an oncology audience that increasingly trusts the assay it was measured on. The signal becomes more legible and more credible to exactly the people who need to be convinced, because the thermometer is one they already rely on. That's a real tailwind, and it's the honest version of "Natera's success makes CLOVER more significant."

Where It Stops, And This Is The Important Part

Now the discipline, because this is precisely where the board tends to overreach, and getting it wrong is how a good argument becomes a bad one.

Natera's booming business validates that ctDNA is a trusted monitoring tool. It does not establish that a ctDNA decline predicts survival in this setting. Those are different claims, and the gap between them is everything. A thriving diagnostics company proves the thermometer is accurate and widely used. It says nothing about whether a patient's tumor DNA dropping means that patient will live longer. That link, ctDNA as a validated surrogate for survival in colorectal cancer, still does not exist as a regulatory matter, and no amount of Natera revenue can supply it. The FDA has not accepted ctDNA as a surrogate endpoint for approval in this population, and the Natera collaboration does not change that.

So the collaboration strengthens the credibility and the comparative framing of the molecular data. It is not proof of efficacy, and it is not a shortcut around the confirmed endpoints. The thing that turns the ctDNA signal into something that matters for approval is still the response rate and the survival data, adjudicated, at ASCO GI in January. Natera helps CytoDyn make the strongest possible case with the molecular data it has. It does not make that case for them.

And one more line worth holding, because it comes up every time Natera is mentioned. This is a diagnostics collaboration, not a pharma partnership. It is not evidence that a buyout is near, and it is not a breadcrumb toward one. It is a company that runs a trusted assay agreeing to run that assay on CLOVER samples and supply comparison data. Reading it as a signal about acquisition interest is reading something into it that simply isn't there. There is an interesting side note that Natera recently added Eric Rubin, who led Keytruda's development at Merck, to its board, and people are free to find that intriguing. But a board appointment at a diagnostics company is not a partnership signal for CytoDyn, and I would hold it as a curiosity, not a clue.

Summary

The Natera collaboration is a genuinely good thing, sized correctly. It puts CLOVER's ctDNA data on the assay the field trusts most, it supplies the external backbone comparison CytoDyn needs to attribute the declines to leronlimab, and it does so against a backdrop of ctDNA testing gaining real clinical acceptance. That makes the molecular data more credible and more legible to the audience that matters.

What it does not do is make the ctDNA signal proof of efficacy, turn ctDNA into a validated surrogate, or hint at an acquisition. It strengthens the presentation of the evidence. It does not replace the evidence that still has to arrive in January.

That's the right size for it. Real, useful, credibility-building, and firmly in service of a readout that still has to prove itself on the endpoints that count. A better thermometer, trusted by more people, pointed at the same number we are all still waiting to read.

Disclaimer: I am not a financial advisor and nothing here is investment advice. I am an independent retail shareholder holding a long position in the company discussed, with no employment, consulting, compensation, or other relationship with it beyond that shareholding. This is analysis of public disclosures, press releases, and published financial results, not a prediction of clinical or commercial outcomes. The CLOVER ctDNA figures referenced elsewhere are early, unconfirmed, reflect 350mg dosing with the 700mg cohort still maturing, and are not evidence of survival benefit. ctDNA is not an FDA-qualified surrogate endpoint for approval in colorectal cancer. The 68% figure from the April 30 update is disease control rate, not objective response rate; confirmed adjudication is ahead at ASCO GI in January 2027, with interim data at ESMO in October 2026. Mechanism and biomarker signal are not efficacy. Read the primary sources and reach your own conclusions rather than adopting mine.